KEYMED BIO-B (02162) saw its shares rise more than 3% again. At the time of writing, the stock was up 2.21%, trading at HK$55.5, with a turnover of HK$7.5096 million. On the news front, KEYMED BIO announced that AstraZeneca PLC has initiated a multicenter, randomized controlled Phase III clinical study (CLARITY-Gastric02) for AZD0901 in combination with capecitabine, with or without rilvegostomig, as a first-line treatment for Claudin18.2-positive, HER2-negative advanced/metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma. The first patient has been dosed in the study. According to the terms of the licensing agreement, the dosing of the first patient triggered a milestone payment totaling $45 million. AstraZeneca PLC has already paid this milestone amount. Public information shows that KYM Biosciences Inc., a joint venture established by KEYMED BIO and Lepu Biopharma (with KEYMED BIO holding a 70% stake), entered into a global exclusive licensing agreement with AstraZeneca PLC in February 2023, granting AstraZeneca global rights to develop and commercialize CMG901.